Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ambroxol + levocetirizine
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest Levo New is an approved, prescription-only oral fixed-dose combination tablet developed and marketed by Centaur Pharmaceuticals in India. It contains two active ingredients: levocetirizine (5 mg), a second-generation, non-sedating H1-receptor antagonist, and ambroxol (60 mg), a mucolytic agent. Levocetirizine selectively blocks histamine H1 receptors to alleviate allergic symptoms such as sneezing, runny nose, watery eyes, and itching. Ambroxol acts as a secretolytic and mucokinetic agent, thinning and loosening thick mucus in the airways by stimulating surfactant production and modulating glucosylceramidase activity, which facilitates expectoration. Together, this combination is indicated for the symptomatic treatment of productive cough associated with allergic respiratory conditions, including allergic rhinitis, common cold, bronchitis, sinusitis, and chronic obstructive pulmonary disease (COPD).
- Brand names
- Sinarest Levo New
- Other names
- ambroxol hydrochloride + levocetirizine dihydrochloridelevocetirizine + ambroxollevocetirizine dihydrochloride + ambroxol hydrochloridelevocetirizine hydrochloride + ambroxol hydrochloride
02
Targets
GBA1 (Glucosylceramidase)HRH1 (Histamine H1 Receptor)GBA2 (Beta-glucosidase 2)SCN10A (Sodium channel protein type X alpha subunit)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)NaV alpha (Voltage-gated sodium channel alpha subunit family)sGC (Soluble Guanylyl Cyclase)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on ambroxol + levocetirizine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ambroxol + levocetirizine.